Spender, Lindsay


Calculated based on number of publications stored in Pure and citations from Scopus
1998 …2024

Research activity per year

Personal profile


Lindsay graduated from The University of Birmingham, U.K. before working in the pharmaceutical industry for four years helping to identify novel anti-viral therapeutic agents. She was then accepted on the Welcome Prize Studentship programme to study for a PhD in immunology at Imperial College, London, where she carried out research into the pathological effects of a common childhood respiratory virus. Lindsay then joined Professor Paul Farrell’s laboratory in the Ludwig Institute for Cancer Research, London as a postdoctoral scientist working on B-cell lymphomas and Epstein-Barr virus. In 2004, Lindsay moved to join Professor Gareth Inman’s lab at The Beatson Institute for Cancer Research in Glasgow to study the mechanisms of TGF-β-induced tumour suppressor activity in human B cells and B cell lymphomas and then moved to  University of Dundee, School of Medicine at Ninewells Hospital in 2010 where she continued as senior postdoctoral scientist in Gareth’s lab. Lindsay is now senior postdoctoral scientist and lab manager in Professor Russell Petty’s lab in Molecular and Clinical Medicine, Ninewells Medical School working on drug resistance mechanisms in oesophageal cancer. Lindsay’s work is supported by the Ninewells Cancer Campaign and Chief Scientist Office. This article in The Courier looks at the work undertaken exploring the resistance to treatment experienced by oesophageal squamous cell carcinoma (OSCC) patients. Dundee scientists lead research on ‘forgotten’ cancer as number of patients in Tayside double.



Oesophageal squamous cell carcinoma (OSCC) is a type of cancer of the oesophagus (food-pipe), associated with social deprivation and poverty, and a key public health concern for Scotland where the incidence in women is the highest in the world.  Current treatments are not very effective, and most patients die within 1 year. Our previous research suggests that OSCC patients who have tumours with too much of the EGFR protein benefit from drugs which specifically block EGFR and stop EGFR-positive tumours growing. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. J Clin Oncol. 2017 Jul 10;35(20):2279-2287.  This research lays the foundations for personalised precise treatment. However, all OSCC tumours eventually become resistant to anti-EGFR drugs and tumours regrow. We are studying potential mechanisms of resistance to chemotherapy in OSCC to provide the data needed to deliver clinical trials to accelerate the development of effective treatments for OSCC patients.

UoD Medical School IncuCyte imaging facility
Lindsay provides support and training for all researchers wishing to use the IncuCyte ZOOM and IncuCyte S3 situated in JWCC, Ninewells Hospital. l.spender@dundee.ac.uk for information

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Dive into the research topics where Lindsay Spender is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or